论文部分内容阅读
目的:探讨孟鲁司特联合舒利迭治疗支气管哮喘的临床疗效。方法:将我院2010年1月—2011年4月收治的100例支气管哮喘患者随机分为观察组和对照组各50例,对照组在常规治疗的基础上吸入舒利迭治疗,观察组在对照组的基础上采用孟鲁司特治疗,比较两组患者的肺功能改善、临床疗效及哮喘积分。结果:两组患者治疗期间均未出现严重不良反应,观察组治疗的总有效率为92.0%,显著高于对照组的72.0%(P<0.05),且观察组的肺功能改善、哮喘积分显著优于对照组(P<0.05)。结论:孟鲁司特联合舒利迭治疗支气管哮喘疗效较好,能有效改善患者的支气管症状和肺功能。
Objective: To investigate the clinical efficacy of montelukast combined with seretide in the treatment of bronchial asthma. Methods: One hundred cases of bronchial asthma admitted to our hospital from January 2010 to April 2011 were randomly divided into observation group (50 cases) and control group (50 cases). The control group was treated with seretide on the basis of routine treatment. The observation group The control group based on the use of montelukast treatment, lung function improvement, clinical efficacy and asthma scores were compared between the two groups. Results: There was no serious adverse reaction during the treatment in both groups. The total effective rate in the observation group was 92.0%, significantly higher than that in the control group (72.0%, P <0.05). The lung function of the observation group was improved and the asthma score was significantly higher Better than the control group (P <0.05). Conclusion: Montelukast combined with seretide is effective in treating bronchial asthma, which can effectively improve bronchial symptoms and lung function in patients.